Julien Viot

ORCID: 0000-0001-7792-0110
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Cancer Research and Treatments
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Ferroptosis and cancer prognosis
  • Metastasis and carcinoma case studies
  • Radiomics and Machine Learning in Medical Imaging
  • RNA modifications and cancer
  • Immune Cell Function and Interaction
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • CAR-T cell therapy research
  • Cancer Cells and Metastasis
  • Cancer survivorship and care
  • Cancer-related cognitive impairment studies
  • Advanced Breast Cancer Therapies
  • Sleep and related disorders
  • Cancer Diagnosis and Treatment
  • Cancer-related molecular mechanisms research
  • Genetic factors in colorectal cancer
  • Breast Cancer Treatment Studies
  • Colorectal Cancer Treatments and Studies
  • Bacterial Infections and Vaccines
  • AI in cancer detection
  • Pneumonia and Respiratory Infections

Centre Hospitalier Universitaire de Besançon
2017-2025

Université de franche-comté
2021-2025

Inserm
2006-2025

Établissement Français du Sang
2025

Methodology and Quality of Life Unit in Oncology
2023-2024

Institut Gustave Roussy
2021-2023

Université Bourgogne Franche-Comté
2020-2022

Centre Hospitalier Universitaire de Bordeaux
2007

Victor (Japan)
2006

Breast Cancer (BC) is the most common type of cancer in women around world and 70% cases are hormone-receptor positive (HR+). In 40% cases, a key mechanism endocrine resistance to standard first line mutation ligand-binding domain (LBD) Estrogen Receptor 1 (ESR1) encoding estrogen receptor α (ER). Most ESR1 mutations that occur at positions 537 538 have been associated with poor clinical outcomes. potential provide neoantigens. This study aims identify if generate specific T cell responses...

10.1186/s13058-025-01962-6 article EN cc-by-nc-nd Breast Cancer Research 2025-02-07

Abstract Metastatic relapse after treatment is the leading cause of cancer mortality, and known resistance mechanisms are missing for most treatments administered to patients. To bridge this gap, we analyze a pan-cancer cohort (META-PRISM) 1,031 refractory metastatic tumors profiled via whole-exome transcriptome sequencing. META-PRISM tumors, particularly prostate, bladder, pancreatic types, displayed transformed genomes compared with primary untreated tumors. Standard-of-care biomarkers...

10.1158/2159-8290.cd-22-0966 article EN cc-by-nc-nd Cancer Discovery 2023-03-02

Tissue-resident memory (TRM) T cells have emerged as key players in cancer immunosurveillance, and their presence has been linked to a favorable clinical outcome solid patients. Liver metastases exhibit highly immunosuppressive tumor microenvironment, however, the role impact of TRM cell infiltration colorectal remain elusive. The expression several tissue residency activation biomarkers investigated on tumor-infiltrating lymphocytes isolated from 26 patients' liver (CRC metastases) compared...

10.1080/2162402x.2025.2455176 article EN cc-by-nc OncoImmunology 2025-01-23

CD226 has been reported to participate in the rescue of CD8+ T cell dysfunction. In this study, we aimed assess prognostic value tumor-infiltrating lymphocytes (TILs) derived from colorectal cancer (CRC) liver metastases treated with chemotherapy and radical surgery. TILs 43 were isolated analyzed ex vivo using flow cytometry. CD155 CD3 levels tumor microenvironment assessed by immunohistochemistry. Exploration validation biological processes highlighted study performed bioinformatics...

10.1038/s41423-023-00978-2 article EN cc-by Cellular and Molecular Immunology 2023-01-30

Combining immunogenic cell death-inducing chemotherapies and PD-1 blockade can generate remarkable tumor responses. It is now well established that TGF-β1 signaling a major component of treatment resistance contributes to the cancer-related immunosuppressive microenvironment. However, whether remains an obstacle immune checkpoint inhibitor efficacy when immunotherapy combined with chemotherapy still be determined. Several syngeneic murine models were used investigate role neutralization on...

10.1080/2162402x.2022.2144669 article EN cc-by-nc OncoImmunology 2022-11-12

Abstract Analyzing the immense diversity of RNA isoforms in large RNA-seq repositories requires laborious data processing using specialized tools. Indexing techniques based on k-mers have previously been effective at searching for sequences across thousands libraries but falling short enabling direct quantification. We show here that RNAs queried form k-mer sets can be quantified seconds, with a precision akin to conventional quantification methods. showcase several applications by exploring...

10.1101/2024.02.27.581927 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2024-03-01

Background The positive role of CD8+ tumor-infiltrating lymphocytes (TIL) in patients with colorectal cancer (CRC) has been well described but the prognostic value CD4 T cell subsets remained to be investigated. In this study, we expanded TIL from surgically resected liver metastases CRC and characterized phenotype expanded-CD4 cells. Methods Liver were 23 CRC. Tumors enzymatically digested cultured high dose interleukin-2 for up 5 weeks. reactivity cultured-T cells measured by flow...

10.1136/jitc-2020-001478 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-11-01

Angiopoietin‐2 (ANGPT2) is a prognostic factor in metastatic colorectal cancer (CRC). Nevertheless, it remains to be elucidated which molecular characteristics make up the ANGPT2‐related poor‐prognosis CRC subset. Public transcriptomic datasets were collected from Gene Expression Omnibus GEO and with TCGAbiolinks R‐package for TCGA. After appropriate normalization, differential expression analysis was performed using Benjamini Hochberg method false discovery rate. Plasma two prospective...

10.1002/ijc.32993 article EN International Journal of Cancer 2020-03-29

Abstract Background Up to 70% of breast cancer patients report symptoms insomnia during and after treatment. Despite the ubiquity symptoms, they are under-screened, under-diagnosed poorly managed in patients. Sleep medications treat but ineffective cure insomnia. Other approaches such as cognitive behavioral therapy for insomnia, relaxation through yoga mindfulness often not available complex implement. An aerobic exercise program could be a promising treatment feasible option management...

10.1186/s12885-023-10902-6 article EN cc-by BMC Cancer 2023-05-17

Colorectal cancer is a public health issue and was the third leading cause of cancer-related death worldwide in 2022. Early diagnosis can improve prognosis, making screening central part colorectal management. Blood-based screening, follow-up patients are possible with study cell-free circulating tumor DNA. This aimed to identify novel DNA methylation biomarkers that be used for cancer. A profile established Gene Expression Omnibus (GEO) database (n = 507) using bioinformatics analysis...

10.1186/s13148-024-01748-1 article EN cc-by-nc-nd Clinical Epigenetics 2024-10-18

Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2- early-stage breast to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expression 21 specific genes from tumor tissue, including Ki67. The primary aim this study assess agreement between Ki67RNA obtained and Ki67IHC. Other objectives were analyze association event free survival (EFS) level Ki67RNA; Ki67RNA. Herein, we report low...

10.1038/s41598-022-07593-7 article EN cc-by Scientific Reports 2022-03-07

Abstract BACKGROUND: Preliminary data has highlighted inherited predisposition to lung cancer related certain genes. The frequency of pathogenic germline variants (PGV) PGV in patients (pts) with according the presence an oncogenic driver is unknown. We studied genes predisposing pts non-small cell (NSCLC), and somatic molecular profile tumors. METHODS: Retrospective study whole exome sequencing (WES) from tissue biopsies performed advanced NSCLC enrolled, after signature inform consent,...

10.1158/1538-7445.am2021-448 article EN Cancer Research 2021-07-01

<div>Abstract<p>Metastatic relapse after treatment is the leading cause of cancer mortality, and known resistance mechanisms are missing for most treatments administered to patients. To bridge this gap, we analyze a pan-cancer cohort (META-PRISM) 1,031 refractory metastatic tumors profiled via whole-exome transcriptome sequencing. META-PRISM tumors, particularly prostate, bladder, pancreatic types, displayed transformed genomes compared primary untreated tumors. Standard-of-care...

10.1158/2159-8290.c.6615885.v3 preprint EN 2024-09-16

Indexing techniques relying on k-mers have proven effective in searching for RNA sequences across thousands of RNA-seq libraries, but without enabling direct quantification. We show here that arbitrary can be quantified seconds through their decomposition into k-mers, with a precision akin to conventional quantification methods. Using an index the Cancer Cell Line Encyclopedia (CCLE) collection consisting 1019 samples, we k-mer indexing offers powerful means reveal non-reference sequences,...

10.1186/s13059-024-03413-5 article EN cc-by Genome biology 2024-10-10
Coming Soon ...